BioXcel Therapeutics

BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in utilizing artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology. The firm offers IGALMI, a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar disorder in adults. It also develops BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of prostate cancer and solid tumors that are refractory to checkpoint inhibitors. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

BioXcel Therapeutics reports FDA approval milestone and financial resilience

BioXcel Therapeutics showcased strong financials with a net revenue of $238,000 and a net loss of $54.8 million, underpinned by a solid cash position of $193.7 million.
The FDA approval of IGALMI and upcoming clinical data announcements demonstrate progress in drug development and commercialization efforts.
While facing challenges such as slow product uptake and operating cost uncertainties, BioXcel has opportunities to drive market penetration through strategic initiatives.
The company's strengths lie in its innovative AI platform, strong cash reserves, and proactive approach to advancing its pipeline and commercialization strategies.

BioXcel Therapeutics reports Q1 progress, eyes revenue growth opportunities

BioXcel Therapeutics showcased strong commercial and clinical progress in Q1 2023 earnings call.
While facing challenges in dose selection and strategic options, the company remains optimistic about revenue growth.
Opportunities lie in maintaining commercial metrics, advancing clinical pipeline, and leveraging FDA-approved products.

BioXcel Therapeutics reports Q2 results, refocuses strategy for growth

BioXcel Therapeutics navigated challenges from investigator misconduct by refocusing on key therapeutic areas and strategic partnerships for financial stability.
Despite workforce reductions and operational changes, the company remains committed to advancing treatments for neurological disorders and sharing progress transparently.
Ongoing FDA discussions, positive trial results, and strategic reprioritization position BioXcel Therapeutics for potential growth and regulatory milestones.

BioXcel Therapeutics advances clinical programs and secures financial backing

BioXcel Therapeutics showcased progress in clinical programs and financial flexibility, with a focus on Alzheimer's-related opportunities.
Challenges include ongoing safety discussions, cash burn rate management, and logistical complexities in home setting trials.
Opportunities lie in targeting underserved markets, regulatory support, economic alleviation for hospitals, and efficient program advancement.
Balancing financial strategies and ensuring data integrity and regulatory alignment are key priorities for BioXcel's future success.

BioXcel Therapeutics reports strong Q4 results and advances clinical programs

BioXcel Therapeutics showcased positive financial performance and progress in late-stage clinical programs, indicating a promising outlook for the company's future.
While facing challenges such as trial timing reevaluation and funding uncertainties, the company's proactive approach and strategic focus present opportunities for growth and innovation.
By leveraging its strengths in program development and financial planning, BioXcel Therapeutics can navigate challenges and capitalize on opportunities to drive value for stakeholders.

BioXcel Therapeutics reports robust Q1 performance and advances late-stage programs

BioXcel Therapeutics demonstrated strong financial performance in Q1 2024, with notable revenue growth and reduced net losses. The company's focus on expanding market potential, advancing late-stage programs, and strengthening intellectual property positions it well for future growth. Challenges include sustaining commercialization success and managing expenses effectively.

BioXcel Therapeutics excels in Q2 with strong financial and clinical performance

BioXcel Therapeutics demonstrated strong financial and clinical performance in Q2 2024, with revenue growth, reduced expenses, and promising outcomes in key programs.
The company's strategic focus on expanding into home settings, addressing unmet needs, and exploring innovative therapies positions it well for sustained growth and value creation.
While facing challenges in execution and financial management, BioXcel Therapeutics has opportunities to leverage its strengths, drive innovation, and establish market leadership in mental health treatment.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioXcel Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of artificial intelligence solutions in neuroscience and immuno-oncology. It also focuses on utilizing technology and research to develop therapeutics solutions. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) between December 15, 2021 and June 28, 2023, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 5, 2023. SO WHAT: If you purchased BioXcel Therapeutics securit.

EQUITY ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages BioXcel Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – BTAI

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (NASDAQ: BTAI) securities between December 15, 2021 and June 28, 2023, inclusive (the “Class Period”). BioXcel investors have until September 5, 2023 to file a lead plaintiff motion. Investors suffering losses on their BioXcel investments are encouraged to contact the Law Offices of Howard.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of BioXcel Therapeutics, Inc. (BTAI) Investors

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), announces that it has filed a class action lawsuit in the United States District Court for the District of Connecticut, captioned Martin v. BioXcel Therapeutics, Inc., et al., Case No. 3:23-cv-00915, on behalf of persons and entities that purchased or otherwise acquired BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (NASDAQ: BTAI) securities between December 15, 2021 and June 28, 2023, inclusive (the “Class Period”).

BTAI CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against BioXcel Therapeutics, Inc.

The biotech was in the running for Comeback Stock of the Week. It had tanked significantly after publishing the results of a clinical trial.

Why BioXcel Therapeutics Stock Was Bouncing Back This Week

NEW YORK, NY / ACCESSWIRE / July 7, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of BioXcel Therapeutics, Inc. ("BioXcel" or "the Company") (NASDAQ:BTAI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against BioXcel Therapeutics, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / July 5, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of BioXcel Therapeutics, Inc. ("BioXcel" or "the Company") (NASDAQ:BTAI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against BioXcel Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / July 3, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of BioXcel Therapeutics, Inc. ("BioXcel" or "the Company") (NASDAQ:BTAI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against BioXcel Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / July 1, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of BioXcel Therapeutics, Inc. ("BioXcel" or "the Company") (NASDAQ: BTAI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against BioXcel Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

BioXcel Therapeutics faces regulatory challenges after the FDA found inconsistencies in one of its clinical trial sites, jeopardizing the supplementary approval of its drug, IGALMI. BioXcel's initiated an internal investigation and independent audit in response, but doubts persist about their commitment to regulatory compliance and ethical conduct, potentially impacting their industry reputation. Given the regulatory uncertainties and the company's existing marketing issues, I have revised my investment recommendation to a "Strong Sell" for BioXcel.

BioXcel: Data Integrity Concerns Muddy Regulatory Outlook (Rating Downgrade)

LOS ANGELES, CA / ACCESSWIRE / June 30, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of BioXcel Therapeutics, Inc. ("BioXcel" or "the Company") (NASDAQ:BTAI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against BioXcel Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (NASDAQ: BTAI) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your BioXcel investments or would like to inquire about potentially pursuing claims to recover your loss under the federal secur.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of BioXcel Therapeutics, Inc. (BTAI) on Behalf of Investors

INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against BioXcel Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (NASDAQ: BTAI) investors concerning the Company's possible violations of federal securities laws. On June 29, 2023, BioXcel disclosed that it is conducting an investigation into protocol adherence and data integrity at the principal investigator's trial site in connection with the Company's TRANQUILITY II clinical trial. BioXcel warned th.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of BioXcel Therapeutics, Inc. (BTAI) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)---- $BTAI #BTAI--The Schall Law Firm Announces it is Investigating Claims Against BioXcel Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm.

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against BioXcel Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (NASDAQ: BTAI) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On June 29, 2023, BioXcel disclosed that it is conducting an investigation into protocol adherence and data integrity at the principal investigator's trial site in co.

The Law Offices of Frank R. Cruz Announces Investigation of BioXcel Therapeutics, Inc. (BTAI) on Behalf of Investors

The company said phase 3 trial results for BXCL501 were generally positive. BioXcel said there was a question regarding one of the trial site's investigators.

Why Shares of BioXcel Therapeutics Are Plunging Thursday

BioXcel Therapeutics (NASDAQ: BTAI ) stock is taking a beating on Thursday after the company released its latest clinical trial data. BioXcel Therapeutics notes that its Phase 3 clinical trial of BXCL501, a treatment of Alzheimer's disease-related agitation, met its primary and secondary endpoints.

Why Is BioXcel Therapeutics (BTAI) Stock Down 57% Today?

BioXcel Therapeutics said on Thursday its experimental drug to treat agitation related to Alzheimer's disease met the main goal in a late-stage study, but the results were marred by concerns over data integrity at one of the trial sites.

BioXcel Therapeutics's drug meets key trial goal to treat Alzheimer's patients

BioXcel said Thursday its dissolvable tablet reduced agitation symptoms in Alzheimer's patients. The results could bolster BTAI stock.

BioXcel CEO Vimal Mehta Says This Alzheimer's News Is A 'Huge Win For Society'

Trial met primary endpoint with the 60 mcg dose, with BXCL501 demonstrating a statistically significant 39% greater reduction in PEC score from baseline compared to placebo at 2 hours (p=0.0112)

BioXcel Therapeutics Announces Positive Topline Results From TRANQUILITY II Phase 3 Trial of BXCL501 for Acute Treatment of Alzheimer's Disease-Related Agitation

Ashford

Aravive Inc

At the heart of every idea for short-squeeze stocks to buy is the ability to make a massive amount of money in a short time period. For a quick recap, those attempting to spark a gamma squeeze essentially take the opposite side of the bearish bet.

3 Short-Squeeze Stocks Set for a Spectacular Gamma Squeeze Rally

NEW HAVEN, Conn., June 01, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics, will participate in fireside chats at two upcoming investor conferences. He will be joined by Robert Risinger, M.D., Chief Medical Officer, Neuroscience, and Matt Wiley, Chief Commercial Officer.

BioXcel Therapeutics to Participate at Two Upcoming Investor Conferences

BioXcel has just published the results of the first part of the Serenity III trial in which, although clinically good results, it has not been able to achieve statistically significant. This first part of the trial has served the company to choose a more optimal dose for the second part. The next results of Tranquility II in June constitute one of the main catalysts that BioXcel presents this year 2023.

BioXcel Therapeutics: Serenity III Part 1 Didn't Meet Primary Endpoints, Part 2 Will

BioXcel Therapeutics got approval last year for Igalmi to treat acute agitation in adults with schizophrenia or bipolar disorder. The drug is in a trial to treat patients in an at-home setting.

Why Shares of BioXcel Therapeutics Are Dropping Thursday

Shares of BTAI stock plummeted after BioXcel's Igalmi missed the mark in patients with agitation due to schizophrenia or bipolar disorders. The post BioXcel Stock Crashes 22% As Bid To Double Its Market Appears Less Certain appeared first on Investor's Business Daily.

News for BioXcel Therapeutics Stock (BTAI)